Pharmexa splits

For a small company with two distinct unrelated technologies, the chronic problem is prioritizing which to work on and how to keep two distinct organizational interests glued together. To solve this issue Danish pharmaccine company Pharmexa A/S recently spun out functional genomics play Inoxell A/S with a view to capturing greater value from the spinout's CellScreen target screening technology.

Pharmexa (SSE:MEBIO, Horsham, Denmark), formerly M&E Biotech A/S, has a core technology called AutoVac that is designed to generate a controlled, specific immune response against any self-antigen. MEBIO has five compounds in partnerships including its ME101 anti-TNF-alpha pharmaccine, which is in Phase I/II trials to treat cancer cachexia with partner Ferring Group (Malmo, Sweden)...